These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29058279)

  • 1. Comparison of treatment outcomes of ticagrelor and clopidogrel among patients undergoing percutaneous coronary intervention: A meta-analysis.
    Yang J; Zeng P; Cai WY
    J Huazhong Univ Sci Technolog Med Sci; 2017 Oct; 37(5):675-680. PubMed ID: 29058279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Tang X; Li R; Jing Q; Wang Q; Liu P; Zhang P; Liu Y
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):115-20. PubMed ID: 27010809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Bellemain-Appaix A; O'Connor SA; Silvain J; Cucherat M; Beygui F; Barthélémy O; Collet JP; Jacq L; Bernasconi F; Montalescot G;
    JAMA; 2012 Dec; 308(23):2507-16. PubMed ID: 23287889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
    Steiner S; Moertl D; Chen L; Coyle D; Wells GA
    Thromb Haemost; 2012 Aug; 108(2):318-27. PubMed ID: 22627948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
    Velders MA; Abtan J; Angiolillo DJ; Ardissino D; Harrington RA; Hellkamp A; Himmelmann A; Husted S; Katus HA; Meier B; Schulte PJ; Storey RF; Wallentin L; Gabriel Steg P; James SK;
    Heart; 2016 Apr; 102(8):617-25. PubMed ID: 26848185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
    JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.
    Dong P; Yang X; Bian S
    Med Sci Monit; 2016 Dec; 22():4929-4936. PubMed ID: 27977637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-PCI medication using clopidogrel and ticagrelor in the treatment of patients with acute myocardial infarction.
    Zhu K; Fu Q; Zhang N; Huang YJ; Zhang Q
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4636-41. PubMed ID: 26698262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy and Safety of Prasugrel, Ticagrelor, and Standard-Dose and High-Dose Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis.
    Singh S; Singh M; Grewal N; Khosla S
    Am J Ther; 2016; 23(1):e52-62. PubMed ID: 26448337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
    Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
    J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention.
    Bonello L; Laine M; Thuny F; Paganelli F; Lemesle G; Roch A; Kerbaul F; Dignat-George F; Berbis J; Frere C
    Int J Cardiol; 2016 Aug; 216():190-3. PubMed ID: 27179310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health.
    Park KH; Jeong MH; Ahn Y; Ahn TH; Seung KB; Oh DJ; Choi DJ; Kim HS; Gwon HC; Seong IW; Hwang KK; Chae SC; Kim KB; Kim YJ; Cha KS; Oh SK; Chae JK;
    Int J Cardiol; 2016 Jul; 215():193-200. PubMed ID: 27128530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison.
    Alexopoulos D; Kontoprias K; Gkizas V; Karanikas S; Ziakas A; Barampoutis N; Tsigkas G; Koutsogiannis N; Davlouros P; Patsilinakos S; Karvounis H; Hahalis G; Xanthopoulou I
    Platelets; 2016 Jul; 27(5):420-6. PubMed ID: 26763727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
    Chen Y; Zhang Y; Tang Y; Huang X; Xie Y
    Curr Med Res Opin; 2014 Jan; 30(1):37-49. PubMed ID: 24083626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
    Bernlochner I; Mayer K; Orban M; Morath T; Jaitner J; Rössner L; Gross L; Laugwitz KL; Kastrati A; Sibbing D
    Platelets; 2016 Dec; 27(8):796-804. PubMed ID: 27275651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
    Clemmensen P; Dridi NP; Holmvang L
    Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis appraising high maintenance dose clopidogrel in patients who underwent percutaneous coronary intervention with and without high on-clopidogrel platelet reactivity.
    Ma W; Liang Y; Zhu J; Wang Y; Wang X
    Am J Cardiol; 2015 Mar; 115(5):592-601. PubMed ID: 25613665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.